Loading clinical trials...

Precision Pain Management for Major Abdominal Surgery in Colorectal Surgery | Clinical Trials | Clareo Health

TERMINATEDNA

Precision Pain Management for Major Abdominal Surgery in Colorectal Surgery

NCT03455751•The Cleveland Clinic

Summary

The primary objectives of this study are to evaluate the potential for preoperative pharmacogenomics (PGx) testing to positively influence postoperative opioid use through visual analog scale (VAS) guided administration of narcotic equivalent and lower pain scores as measured by OBAS in patients undergoing major abdominal surgery.

Eligibility

Age

18 - 80 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Subject capable of giving consent
•Age 18-80
•Scheduled for open colorectal resection at Cleveland Clinic main campus (with preoperative appointment scheduled at least five days before date of surgery)

Exclusion Criteria

•Patient does not speak English
•Patient with substance-use disorder (including alcohol)
•Patient diagnosed with major depression
•Patient currently taking opioids
•Previous long-term opioid use (\> 3 months)
•Previous opioid use with a dose of \>100 milligram morphine equivalent (MME)
•Patient has pain-related disorder (e.g. fibromyalgia, sympathetic dystrophy, etc.)
•Documented allergy to pain medication

Locations (1)

Cleveland Clinic

Cleveland, Ohio, United States

Key Dates

Start Date

April 17, 2018

Primary Completion Date

January 9, 2019

Completion Date

January 9, 2019

Last Updated

March 18, 2019

Enrollment

ACTUAL participants

Conditions

Colorectal CancerDiverticular DiseaseCrohn DiseaseUlcerative Colitis

Interventions

PGx-guided post-operative pain management

GENETIC

Clinical Trial of an Anti-cancer Drug, CA-4948 (Emavusertib), in Combination With Chemotherapy Treatment (FOLFOX Plus Bevacizumab) in Metastatic Colorectal Cancer

NCT06696768

Metastatic Colorectal AdenocarcinomaStage III Colorectal Cancer AJCC v8+2 more

View study

RECRUITINGPHASE1

Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial

NCT04704661

Advanced Breast CarcinomaAdvanced Colon Carcinoma+38 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: March 18, 2019Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Precision Pain Management for Major Abdominal Surgery in Colorectal Surgery

Inclusion Criteria

Exclusion Criteria

Clinical Trial of an Anti-cancer Drug, CA-4948 (Emavusertib), in Combination With Chemotherapy Treatment (FOLFOX Plus Bevacizumab) in Metastatic Colorectal Cancer

Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial

Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)

A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors

Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors

Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatment or Approved Cancer Treatment Alone in Patients w/ Metastatic Colorectal Cancer w/Liver Dominant Disease